Compare Stocks: RADX, SPRB, IFRX, and TLSA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IFRX InflaRx	$2.00 +2.0%	$1.88	$0.78 ▼ $2.95	$141.69M	2.48	858,596 shs	491,370 shs
RADX Radiopharm Theranostics	$2.86 +2.1%	$4.00	$2.62 ▼ $16.25	$36.67M	1.63	142,493 shs	29,460 shs
SPRB Spruce Biosciences	$46.41 +0.5%	$48.44	$7.00 ▼ $240.00	$127.15M	3.23	55,943 shs	24,251 shs
TLSA Tiziana Life Sciences	$1.01	$1.12	$0.87 ▼ $2.47	$128.53M	0.49	616,418 shs	414,676 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IFRX InflaRx	+2.04%	+12.36%	-2.44%	-20.63%	+143.01%
RADX Radiopharm Theranostics	+2.14%	-2.05%	-34.55%	-36.73%	-39.28%
SPRB Spruce Biosciences	+0.45%	+0.32%	-7.31%	-19.36%	+364.80%
TLSA Tiziana Life Sciences	0.00%	+4.38%	-17.89%	-32.67%	-58.94%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IFRX InflaRx	$2.00 +2.0%	$1.88	$0.78 ▼ $2.95	$141.69M	2.48	858,596 shs	491,370 shs
RADX Radiopharm Theranostics	$2.86 +2.1%	$4.00	$2.62 ▼ $16.25	$36.67M	1.63	142,493 shs	29,460 shs
SPRB Spruce Biosciences	$46.41 +0.5%	$48.44	$7.00 ▼ $240.00	$127.15M	3.23	55,943 shs	24,251 shs
TLSA Tiziana Life Sciences	$1.01	$1.12	$0.87 ▼ $2.47	$128.53M	0.49	616,418 shs	414,676 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IFRX InflaRx	+2.04%	+12.36%	-2.44%	-20.63%	+143.01%
RADX Radiopharm Theranostics	+2.14%	-2.05%	-34.55%	-36.73%	-39.28%
SPRB Spruce Biosciences	+0.45%	+0.32%	-7.31%	-19.36%	+364.80%
TLSA Tiziana Life Sciences	0.00%	+4.38%	-17.89%	-32.67%	-58.94%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IFRX InflaRx	2.88	Moderate Buy	$7.33	266.67% Upside
RADX Radiopharm Theranostics	2.33	Hold	$11.00	284.62% Upside
SPRB Spruce Biosciences	2.64	Moderate Buy	$162.63	250.41% Upside
TLSA Tiziana Life Sciences	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest RADX, SPRB, IFRX, and TLSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	IFRX InflaRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
7/27/2026	IFRX InflaRx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/17/2026	RADX Radiopharm Theranostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/14/2026	TLSA Tiziana Life Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/13/2026	SPRB Spruce Biosciences	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$160.00
6/24/2026	IFRX InflaRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/16/2026	SPRB Spruce Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$123.00
6/16/2026	SPRB Spruce Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$123.00
6/9/2026	SPRB Spruce Biosciences	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$135.00
6/5/2026	SPRB Spruce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/4/2026	RADX Radiopharm Theranostics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IFRX InflaRx	-$10.10K	-14,314.03	N/A	N/A	$2.35 per share	0.85
RADX Radiopharm Theranostics	$2.35M	15.94	N/A	N/A	$3.52 per share	0.81
SPRB Spruce Biosciences	$4.91M	25.99	N/A	N/A	$39.72 per share	1.17
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IFRX InflaRx	-$51.63M	-$0.58	N/A	N/A	N/A	N/A	-53.56%	-43.02%	N/A
RADX Radiopharm Theranostics	-$24.83M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	-$38.97M	-$36.60	N/A	N/A	N/A	N/A	-155.40%	-101.67%	8/13/2026 (Estimated)
TLSA Tiziana Life Sciences	-$18.43M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/18/2026 (Estimated)

Latest RADX, SPRB, IFRX, and TLSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	SPRB Spruce Biosciences	-$5.79	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	IFRX InflaRx	-$0.0666	-$0.11	-$0.0434	-$0.10	$0.01 million	N/A
5/13/2026	Q1 2026	SPRB Spruce Biosciences	-$7.9340	-$8.94	-$1.0060	-$8.94	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
RADX Radiopharm Theranostics	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IFRX InflaRx	N/A	8.22	8.22
RADX Radiopharm Theranostics	N/A	3.01	N/A
SPRB Spruce Biosciences	0.16	4.67	4.67
TLSA Tiziana Life Sciences	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IFRX InflaRx	42.39%
RADX Radiopharm Theranostics	N/A
SPRB Spruce Biosciences	91.71%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
IFRX InflaRx	16.30%
RADX Radiopharm Theranostics	N/A
SPRB Spruce Biosciences	4.30%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IFRX InflaRx	60	72.29 million	60.51 million	Optionable
RADX Radiopharm Theranostics	N/A	13.10 million	N/A	N/A
SPRB Spruce Biosciences	20	2.75 million	2.63 million	Optionable
TLSA Tiziana Life Sciences	8	127.26 million	76.58 million	Optionable

RADX, SPRB, IFRX, and TLSA Headlines

Recent News About These Companies

Insider Buying: Tiziana Life Sciences (NASDAQ:TLSA) CEO Acquires $81,292.79 in Stock

August 7, 2026 | insidertrades.com

Insider Buying: Tiziana Life Sciences (NASDAQ:TLSA) CEO Purchases 83,807 Shares of Stock

August 6, 2026 | marketbeat.com

Ivor Elrifi Acquires 237,616 Shares of Tiziana Life Sciences (NASDAQ:TLSA) Stock

August 6, 2026 | marketbeat.com

Tiziana Life Sciences (NASDAQ:TLSA) CEO Purchases $667,000.00 in Stock

August 6, 2026 | insidertrades.com

Tiziana Life Sciences (NASDAQ:TLSA) CEO Ivor Elrifi Purchases 667,000 Shares

August 5, 2026 | marketbeat.com

Tiziana Life Sciences Ltd.: Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

August 2, 2026 | finanznachrichten.de

Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition

July 31, 2026 | benzinga.com

Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient

July 31, 2026 | proactiveinvestors.com

Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

July 31, 2026 | finance.yahoo.com

Tiziana Life Sciences (NASDAQ:TLSA) Rating Increased to Hold at Zacks Research

July 16, 2026 | marketbeat.com

Tiziana Life Sciences (NASDAQ:TLSA) Shares Up 8.1% - What's Next?

July 13, 2026 | marketbeat.com

Tiziana Life Sciences (NASDAQ:TLSA) Stock, Short Interest Report

July 13, 2026 | benzinga.com

Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial

June 25, 2026 | proactiveinvestors.com

Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial

June 25, 2026 | globenewswire.com

Why Tiziana Life Sciences Is Back on the Small-Cap Radar?

June 19, 2026 | kalkinemedia.comK

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

June 15, 2026 | globenewswire.com

Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

May 29, 2026 | finanznachrichten.de

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

May 28, 2026 | globenewswire.com

Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data â€“ ICYMI

May 22, 2026 | proactiveinvestors.com

Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI

May 22, 2026 | proactiveinvestors.com

Tiziana Life Sciences Stock Rises Over 9% After Multiple Sclerosis Trial Enrollment Update

May 21, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX, SPRB, IFRX, and TLSA Company Descriptions

InflaRx NASDAQ:IFRX

$2.00 +0.04 (+2.04%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$2.00 0.00 (0.00%)

As of 08/11/2026 07:34 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Radiopharm Theranostics NASDAQ:RADX

$2.86 +0.06 (+2.14%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$2.65 -0.21 (-7.27%)

As of 04:11 AM Eastern

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

Spruce Biosciences NASDAQ:SPRB

$46.41 +0.21 (+0.45%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$46.40 -0.01 (-0.02%)

As of 08/11/2026 07:34 PM Eastern

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Tiziana Life Sciences NASDAQ:TLSA

$1.01 0.00 (0.00%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$1.01 0.00 (0.00%)

As of 08/11/2026 07:46 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RADX, SPRB, IFRX, and TLSA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RADX, SPRB, IFRX, and TLSA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RADX, SPRB, IFRX, and TLSA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX, SPRB, IFRX, and TLSA Company Descriptions

InflaRx NASDAQ:IFRX

Radiopharm Theranostics NASDAQ:RADX

Spruce Biosciences NASDAQ:SPRB

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RADX, SPRB, IFRX, and TLSA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RADX, SPRB, IFRX, and TLSA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RADX, SPRB, IFRX, and TLSA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX, SPRB, IFRX, and TLSA Company Descriptions

InflaRx NASDAQ:IFRX

Radiopharm Theranostics NASDAQ:RADX

Spruce Biosciences NASDAQ:SPRB

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools